PARP

Merck and Hengrui Unite for Pioneering Cancer Therapies Worldwide

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This…

6 months ago

AstraZeneca: Exciting ROpel Phase III trial results demonstrate the potential for Lynparza with abiraterone to become a new 1st-line option for patients with metastatic castration-resistant prostate cancer

(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive…

3 years ago

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed…

6 years ago